About the project

 

V.A. Cure is a European MSCA-ITN network aiming to uncover core mechanisms of initiation and maintenance of Vascular Anomalies (VAs) and to leverage this information for establishing novel therapeutic strategies. The network consortium consists of 7 academic laboratories and 2 companies from across Europe, and is supported by 8 partner organisations (5 companies, one university, one hospital and a patient organization).

The 14 Early Stage Researchers (ESRs) will be a part of  the unique PhD program, consisting of an individual research project, the network’s training programme, intersectoral secondments and outreach activities. Project goal is to  ensure a comprehensive perception of the research and drug/technology development in pharma industry/biotech and academia.

The individual research is a part of the V.A. Cure project, which is developed in four stages:

14 Early Stage Researchers to research the causes and mechanisms of aberrant vascular function   A comprehensive training programme provided by experts in vascular biology from across Europe   International cooperation on vascular anomalies research with participating organisations from across the whole chain



. @castrorakel, Director of Social Policy @eurordis highlights need for #HolisticCare in @thetimes report “There is an urgent need to provide holistic care that covers the spectrum of health, social & everyday needs of people living with a rare disease” https://t.co/NbvMgXL0RU https://t.co/ufEpw3JwyV

Project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 814316